<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="research-article" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molecules</journal-id>
      <journal-title>Molecules</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molecules</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molecules</abbrev-journal-title>
      <issn pub-type="epub">1420-3049</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/molecules21020189</article-id>
      <article-id pub-id-type="publisher-id">molecules-21-00189</article-id>
      <article-categories>
        <subj-group>
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ghorab</surname>
            <given-names>Mostafa M.</given-names>
          </name>
          <xref rid="af1-molecules-21-00189" ref-type="aff">1</xref>
          <xref rid="af2-molecules-21-00189" ref-type="aff">2</xref>
          <xref rid="c1-molecules-21-00189" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alsaid</surname>
            <given-names>Mansour S.</given-names>
          </name>
          <xref rid="af1-molecules-21-00189" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Al-Dosari</surname>
            <given-names>Mohammed S.</given-names>
          </name>
          <xref rid="af1-molecules-21-00189" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>El-Gazzar</surname>
            <given-names>Marwa G.</given-names>
          </name>
          <xref rid="af2-molecules-21-00189" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Parvez</surname>
            <given-names>Mohammad K.</given-names>
          </name>
          <xref rid="af1-molecules-21-00189" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Vanden Eynde</surname>
            <given-names>Jean Jacques</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Mayence</surname>
            <given-names>Annie</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-molecules-21-00189"><label>1</label>Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; <email>msalsaid@ksu.edu.sa</email> (M.S.A.); <email>msdosari@yahoo.com</email> (M.S.A.-D.); <email>khalid_parvez@yahoo.com</email> (M.K.P.)</aff>
      <aff id="af2-molecules-21-00189"><label>2</label>Department of Drug Radiation Research, National Center for Radiation Research and Technology, Atomic Energy Authority, P.O. Box 29, Nasr City, Cairo 11371, Egypt; <email>marwagalalgazzar@yahoo.com</email></aff>
      <author-notes>
        <corresp id="c1-molecules-21-00189"><label>*</label>Correspondence: <email>mmsghorab@yahoo.com</email>; Tel.: +966-53-4292-860; Fax: +966-1-4670-560</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>02</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection"><month>02</month>
        <year>2016</year>
      </pub-date>
      <volume>21</volume>
      <issue>2</issue>
      <elocation-id>189</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>01</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>By combining the structural features of quinazoline and sulfonamides, novel hybrid compounds <bold>2</bold>&#x2013;<bold>21</bold> were synthesized using a simple and convenient method. Evaluation of these compounds against different cell lines identified compounds <bold>7</bold> and <bold>17</bold> as most active anticancer agents as they showed effectiveness on the four tested cell lines. The anticancer screening results of the tested compounds provides an encouraging framework that could lead to the development of potent new anticancer agents.</p>
      </abstract>
      <kwd-group>
        <kwd>synthesis</kwd>
        <kwd>quinazoline</kwd>
        <kwd>sulfonamides</kwd>
        <kwd>anticancer activity</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-molecules-21-00189" sec-type="intro">
      <title>1. Introduction</title>
      <p>Cancer continues to be a leading health problem in developed as well as developing countries. It has become the number one killer due to various worldwide factors [<xref ref-type="bibr" rid="B1-molecules-21-00189">1</xref>,<xref ref-type="bibr" rid="B2-molecules-21-00189">2</xref>,<xref ref-type="bibr" rid="B3-molecules-21-00189">3</xref>,<xref ref-type="bibr" rid="B4-molecules-21-00189">4</xref>,<xref ref-type="bibr" rid="B5-molecules-21-00189">5</xref>]. This enormous incidence of cancer has increased the urgency of the search for the latest, safer and efficacious anticancer agents, aiming at the prevention or the cure of this illness [<xref ref-type="bibr" rid="B6-molecules-21-00189">6</xref>,<xref ref-type="bibr" rid="B7-molecules-21-00189">7</xref>,<xref ref-type="bibr" rid="B8-molecules-21-00189">8</xref>]. In the efforts to identify various chemical substances which may serve as leads for designing novel anticancer agents, nitrogen- and sulfur- containing heterocycles are of particular interest [<xref ref-type="bibr" rid="B9-molecules-21-00189">9</xref>,<xref ref-type="bibr" rid="B10-molecules-21-00189">10</xref>,<xref ref-type="bibr" rid="B11-molecules-21-00189">11</xref>]. Quinazoline and sulfonamide moieties have been identified as classes of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumors. In recent years, quinazolines, as an important pharmacophore, have emerged as a versatile template for inhibition of a diverse range of receptor tyrosine kinases [<xref ref-type="bibr" rid="B12-molecules-21-00189">12</xref>,<xref ref-type="bibr" rid="B13-molecules-21-00189">13</xref>,<xref ref-type="bibr" rid="B14-molecules-21-00189">14</xref>,<xref ref-type="bibr" rid="B15-molecules-21-00189">15</xref>,<xref ref-type="bibr" rid="B16-molecules-21-00189">16</xref>]. The most widely studied of these is the epidermal growth factor receptor (EGFR), with the small-molecule inhibitor gefitinib being the first quinazoline derivative to be approved for the treatment of Non-Small Cell Lung Cancer [<xref ref-type="bibr" rid="B17-molecules-21-00189">17</xref>,<xref ref-type="bibr" rid="B18-molecules-21-00189">18</xref>,<xref ref-type="bibr" rid="B19-molecules-21-00189">19</xref>,<xref ref-type="bibr" rid="B20-molecules-21-00189">20</xref>,<xref ref-type="bibr" rid="B21-molecules-21-00189">21</xref>]. Subsequent research aimed at further exploration of the SAR of this novel template has led to discovery of highly selective compounds that target EGFR such as erlotinib, lapatinib, canertinib and vandetanib [<xref ref-type="bibr" rid="B22-molecules-21-00189">22</xref>,<xref ref-type="bibr" rid="B23-molecules-21-00189">23</xref>,<xref ref-type="bibr" rid="B24-molecules-21-00189">24</xref>] (<xref ref-type="fig" rid="molecules-21-00189-f001">Figure 1</xref>). These compounds act via competing with ATP for binding at the catalytic domain of tyrosine kinase. Later on, a great structural variety of compounds of structurally diverse classes have proved to be highly potent and selective ATP-competitive inhibitors [<xref ref-type="bibr" rid="B25-molecules-21-00189">25</xref>,<xref ref-type="bibr" rid="B26-molecules-21-00189">26</xref>,<xref ref-type="bibr" rid="B27-molecules-21-00189">27</xref>,<xref ref-type="bibr" rid="B28-molecules-21-00189">28</xref>]. Based on the good performances of quinazoline derivatives in anticancer applications, the development of novel quinazoline derivatives as anticancer drugs is a promising field. </p>
      <p>Varied biological activities have been attributed to sulfonamide compounds, including carbonic anhydrase inhibition, antitumoral, antimalarial and antimicrobial activities [<xref ref-type="bibr" rid="B29-molecules-21-00189">29</xref>,<xref ref-type="bibr" rid="B30-molecules-21-00189">30</xref>,<xref ref-type="bibr" rid="B31-molecules-21-00189">31</xref>]. In the design of new drugs, the development of hybrid molecules through the combination of different pharmacophores may lead to compounds with interesting biological profiles [<xref ref-type="bibr" rid="B32-molecules-21-00189">32</xref>]. In view of the abovementioned knowledge about different pharmacophores and in continuation of our research programme [<xref ref-type="bibr" rid="B33-molecules-21-00189">33</xref>,<xref ref-type="bibr" rid="B34-molecules-21-00189">34</xref>,<xref ref-type="bibr" rid="B35-molecules-21-00189">35</xref>,<xref ref-type="bibr" rid="B36-molecules-21-00189">36</xref>,<xref ref-type="bibr" rid="B37-molecules-21-00189">37</xref>,<xref ref-type="bibr" rid="B38-molecules-21-00189">38</xref>,<xref ref-type="bibr" rid="B39-molecules-21-00189">39</xref>,<xref ref-type="bibr" rid="B40-molecules-21-00189">40</xref>,<xref ref-type="bibr" rid="B41-molecules-21-00189">41</xref>,<xref ref-type="bibr" rid="B42-molecules-21-00189">42</xref>,<xref ref-type="bibr" rid="B43-molecules-21-00189">43</xref>,<xref ref-type="bibr" rid="B44-molecules-21-00189">44</xref>,<xref ref-type="bibr" rid="B45-molecules-21-00189">45</xref>], we have now synthesized quinazoline-sulfonamide hybrids to obtain a single molecular framework incorporating both moieties. These hybrid molecules consist of a planar heterocyclic ring (quinazoline) with a hydrophobic phenyl ring at position-2 as a central core that can act as a scaffold to carry a functionalized branch at position-4, in such a way to accommodate a sulfonamide moiety (<xref ref-type="fig" rid="molecules-21-00189-f002">Figure 2</xref>). Introduction of the benzensulfonamide amino group at position-4 will add a new hydrogen bond donor, a very much needed characteristic for the desired activity [<xref ref-type="bibr" rid="B46-molecules-21-00189">46</xref>]. These compounds were then screened for their <italic>in vitro</italic> anticancer activity against various cell lines.</p>
      <fig id="molecules-21-00189-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>EGFR-tyrosine kinase inhibitors.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-21-00189-g001.tif"/>
      </fig>
      <fig id="molecules-21-00189-f002" position="float">
        <label>Figure 2</label>
        <caption>
          <p>The designed quinazoline-sulfonamide hybrids.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-21-00189-g002.tif"/>
      </fig>
    </sec>
    <sec id="sec2-molecules-21-00189" sec-type="results">
      <title>2. Results and Discussion</title>
      <sec id="sec2dot1-molecules-21-00189">
        <title>2.1. Chemistry</title>
        <p>The aim of this work was to design and synthesize novel quinazoline-sulfonamide hybrids to evaluate their anticancer activity. Thus, interaction of 4-chloro-2-phenylquinazoline (<bold>1</bold>) with several sulfonamides in dry <italic>N</italic>,<italic>N</italic>-dimethylformamide afforded the corresponding quinazoline-sulfonamide derivatives <bold>2</bold>&#x2013;<bold>18</bold> (<xref ref-type="scheme" rid="molecules-21-00189-f003">Scheme 1</xref>). The structures of the formed compounds were confirmed on the basis of elemental analyses and spectral data. Thus, the IR spectra of compounds <bold>2</bold>&#x2013;<bold>18</bold> showed absorption bands for (NH), (CH aromatic), (CH aliphatic), (C=N) and (SO<sub>2</sub>) functional groups. The <sup>1</sup>H-NMR spectra exhibited singlets assigned to the NH group which were exchanged upon deuteration. Also, interaction of compound <bold>1</bold> with sulfanilamide in dimethylformamide in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> furnished 4-amino-<italic>N</italic>-(2-phenylquinazoline-4-yl)-benzenesulfonamide (<bold>19</bold>, <xref ref-type="scheme" rid="molecules-21-00189-f004">Scheme 2</xref>), this reaction proceeded through salt formation of the acidic amino group of sulfonamide (SO<sub>2</sub>NH<sub>2</sub>) which further reacted with the chloro group of the quinazoline to yield compound <bold>19</bold>. </p>
        <fig id="molecules-21-00189-f003" position="float">
          <object-id pub-id-type="pii">molecules-21-00189-f003_Scheme 1</object-id>
          <label>Scheme 1</label>
          <caption>
            <p>Synthetic pathways for compounds <bold>2</bold>&#x2013;<bold>18</bold>.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-21-00189-g003.tif"/>
        </fig>
        <fig id="molecules-21-00189-f004" position="float">
          <object-id pub-id-type="pii">molecules-21-00189-f004_Scheme 2</object-id>
          <label>Scheme 2</label>
          <caption>
            <p>Synthetic pathways for compounds <bold>19</bold>&#x2013;<bold>21</bold>.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-21-00189-g004.tif"/>
        </fig>
        <p>The IR spectrum of compound <bold>19</bold> showed characteristic bands at 3412, 3209 cm<sup>&#x2212;1</sup> (NH, NH<sub>2</sub>), 3084 cm<sup>&#x2212;1</sup> (CH aromatic) 1635 cm<sup>&#x2212;1</sup> (C=N), 1375, 1134 cm<sup>&#x2212;1</sup> (SO<sub>2</sub>). The <sup>1</sup>H-NMR spectrum of compound <bold>19</bold> exhibited signals at 7.0 ppm due to the NH<sub>2</sub> group, which exchangeable with D<sub>2</sub>O, and a singlet at 11.9 ppm assigned to the NH group which was exchangeable with D<sub>2</sub>O. The mass spectrum of compound <bold>19</bold> revealed a molecular ion peak <italic>m</italic>/<italic>z</italic> at of 376[M<sup>+</sup>] (11.64). In addition, by interaction of compound <bold>1</bold> with dapsone in 1:1 molar ratio, <italic>N</italic>-(4-(4-aminophenylsulfonyl)phenyl)-2-phenylquinazolin-4-amine (<bold>20</bold>) was formed, while, an additional mole of 2-phenylquinazolin-4-amine was introduced to give the bis-compound <bold>21</bold> under the same reaction conditions but using a 2:1 molar ratio. The structures of compounds <bold>20</bold> and <bold>21</bold> were confirmed on the basis of elemental analyses, IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and mass spectral data. The IR spectrum of compound <bold>20</bold> revealed characteristic bands at 3375, 3257, (NH, NH<sub>2</sub>), 1664 (C=O), 1618 (C=N), 1389, 1140 (SO<sub>2</sub>). The <sup>1</sup>H-NMR spectrum of compound <bold>20</bold> exhibited signals at 5.9 ppm due to a NH<sub>2</sub> group, which was exchangeable with D<sub>2</sub>O, and a singlet at 10.1 ppm assigned to a NH group which was exchangeable with D<sub>2</sub>O. The mass spectrum of compound <bold>20</bold> revealed a molecular ion peak at <italic>m</italic>/<italic>z</italic> 453 [M<sup>+</sup>] (13.72). The IR spectrum of <bold>21</bold> showed characteristic bands at 3367 (2NH), 1622 (2C=N), 1375, 1181 (SO<sub>2</sub>). The <sup>1</sup>H-NMR spectrum of <bold>21</bold> revealed signals at 10.1 ppm corresponding to two NH groups which were exchangeable with D<sub>2</sub>O. The mass spectrum of compound <bold>21</bold> showed a molecular ion peak at <italic>m</italic>/<italic>z</italic> 657 [M<sup>+</sup>] (32.18); this increase in the mass demonstrated the introduction of the second mole of dapsone.</p>
      </sec>
      <sec id="sec2dot2-molecules-21-00189">
        <title>2.2. In-Vitro Anticancer Evaluation</title>
        <p>The synthesized compounds were evaluated for their <italic>in vitro</italic> anticancer activity against human lung cancer cell line (A549), cervical (HeLa) cancer cell line, colorectal cell line (LoVo) and breast cancer cell line (MDA-MB-231) using doxorubicin as reference drug. The relationship between surviving fraction and drug concentration was plotted to obtain the survival curves of the cancer cell lines. The response parameter calculated was the IC<sub>50</sub> value, which corresponds to the concentration required for 50% inhibition of cell viability. The results are presented in <xref ref-type="table" rid="molecules-21-00189-t001">Table 1</xref>, where all compounds exhibit moderate activity compared to doxorubicin as positive control. </p>
        <table-wrap id="molecules-21-00189-t001" position="float">
          <object-id pub-id-type="pii">molecules-21-00189-t001_Table 1</object-id>
          <label>Table 1</label>
          <caption>
            <p><italic>In vitro</italic> anticancer screening of the synthesized compounds against four cell lines. Data are expressed as IC<sub>50</sub> (&#xB5;M) &#xB1; SD (<italic>n</italic> = 3).</p>
          </caption>
          <table>
            <thead>
              <tr>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Cpd. No.</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">A549 (Lung Cancer Cells)</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">HeLa (Cervical)</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">LoVo (Colorectal Cancer Cells)</th>
                <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">MDA-MB-231 (Breast Cancer Cells)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="center" valign="middle">
                  <bold>2</bold>
                </td>
                <td align="center" valign="middle">134.9 &#xB1; 0.40</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">94.9 &#xB1; 0.78</td>
                <td align="center" valign="middle">58.2 &#xB1; 1.76</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>3</bold>
                </td>
                <td align="center" valign="middle">113.5 &#xB1; 1.10</td>
                <td align="center" valign="middle">221.1 &#xB1; 1.22</td>
                <td align="center" valign="middle">80.5 &#xB1; 0.87</td>
                <td align="center" valign="middle">51.4 &#xB1; 1.32</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>4</bold>
                </td>
                <td align="center" valign="middle">129.4 &#xB1; 0.71</td>
                <td align="center" valign="middle">187.7 &#xB1; 1.10</td>
                <td align="center" valign="middle">61.7 &#xB1; 1.31</td>
                <td align="center" valign="middle">36.4 &#xB1; 0.34</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>5</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">212.8 &#xB1; 0.78</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>6</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">217.0 &#xB1; 1.11</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>7</bold>
                </td>
                <td align="center" valign="middle">77.8 &#xB1; 0.54</td>
                <td align="center" valign="middle">91.5 &#xB1; 0.41</td>
                <td align="center" valign="middle">96.5 &#xB1; 0.34</td>
                <td align="center" valign="middle">77.9 &#xB1; 0.36</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>8</bold>
                </td>
                <td align="center" valign="middle">130.4 &#xB1; 0.67</td>
                <td align="center" valign="middle">284.6 &#xB1; 1.03</td>
                <td align="center" valign="middle">160.1 &#xB1; 0.90</td>
                <td align="center" valign="middle">97.4 &#xB1; 1.40</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>9</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">182.5 &#xB1; 0.33</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>10</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">125.4 &#xB1; 0.88</td>
                <td align="center" valign="middle">154.1 &#xB1; 1.12</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>11</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">54.2 &#xB1; 0.92</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>12</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">58.6 &#xB1;0.50</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>13</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">112.9 &#xB1; 0.35</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>14</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">101.7 &#xB1; 0.67</td>
                <td align="center" valign="middle">93.9 &#xB1; 0.45</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>15</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">61.5 &#xB1; 0.01</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>16</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">65.5 &#xB1; 1.65</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>17</bold>
                </td>
                <td align="center" valign="middle">161.6 &#xB1; 0.78</td>
                <td align="center" valign="middle">87.6 &#xB1; 1.00</td>
                <td align="center" valign="middle">97.3 &#xB1; 0.23</td>
                <td align="center" valign="middle">42.8 &#xB1; 1.09</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>18</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">276.0 &#xB1; 1.01</td>
                <td align="center" valign="middle">132.0 &#xB1; 1.04</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>19</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">146.4 &#xB1; 1.34</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>20</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">251.6 &#xB1; 0.98</td>
                <td align="center" valign="middle">72.5 &#xB1; 0.26</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle">
                  <bold>21</bold>
                </td>
                <td align="center" valign="middle">NA</td>
                <td align="center" valign="middle">189.8 &#xB1; 1.12</td>
                <td align="center" valign="middle">73.1 &#xB1; 1.54</td>
                <td align="center" valign="middle">NA</td>
              </tr>
              <tr>
                <td align="center" valign="middle" style="border-bottom:solid thin">Doxorubicin</td>
                <td align="center" valign="middle" style="border-bottom:solid thin">283.5 &#xB1; 0.01</td>
                <td align="center" valign="middle" style="border-bottom:solid thin">120.7 &#xB1; 0.09</td>
                <td align="center" valign="middle" style="border-bottom:solid thin">374.4 &#xB1; 1.00</td>
                <td align="center" valign="middle" style="border-bottom:solid thin">26.5 &#xB1; 0.54</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>NA = Not Active.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>In the case of the human lung cancer cell line (A549) compounds <bold>2</bold>, <bold>3</bold>, <bold>4</bold>, <bold>7</bold>, <bold>8</bold>, and <bold>17</bold> were the most potent, with IC<sub>50</sub> values ranging from 77.8&#x2013;161.6 &#xB5;M, lower than the reference. On the other hand, the tested compounds showed low activity on the HeLa cell line where he most potent were the sulfonamide derivatives <bold>7</bold> and <bold>17</bold> (IC<sub>50</sub> = 91.5 and 87.6 &#xB5;M, respectively). In case of the colorectal cell line LoVo, all compounds showed excellent activity and were found to be more active than doxorubicin. Moderate activity was observed for the synthesized compounds on the MDA-MB-231 breast cancer cell line, where the most potent candidates were compounds <bold>2</bold>&#x2013;<bold>4</bold>, <bold>7</bold>, <bold>8</bold>, <bold>10</bold>, <bold>14</bold> and <bold>17</bold>, which all showed lower activity than the reference drug doxorubicin. Generally, the colorectal (LoVo) and breast (MDA-MB-231) cancer cell lines were the most sensitive to the synthesized compounds. With regard to broad spectrum anticancer activity, close examination of the data presented in <xref ref-type="table" rid="molecules-21-00189-t001">Table 1</xref>, reveals that compounds <bold>7</bold> and <bold>17</bold> were the most active, showing effectiveness toward the four cell lines.</p>
      </sec>
    </sec>
    <sec id="sec3-molecules-21-00189">
      <title>3. Materials and Methods</title>
      <sec id="sec3dot1-molecules-21-00189">
        <title>3.1. General Information</title>
        <p>All analyses were done at the Research Center, King Saud University (Riyadh, Saudi Arabia). Melting points (uncorrected) were determined in open capillaries on a Gallenkamp melting point apparatus (Sanyo Gallenkamp, Southborough, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Darmstadt, Germany) were used for thin layer chromatography. A developing solvent system of 4:1 chloroform/methanol was used and the spots were detected by ultraviolet light. IR spectra (KBr discs) were recorded using an FT-IR spectrometer (Perkin Elmer, Waltham, MA, USA). <sup>1</sup>H-NMR spectra were scanned on NMR spectrometer (Bruker AXS Inc., Flawil, Switzerland), operating at 500 MHz for <sup>1</sup>H- and 125.76 MHz for <sup>13</sup>C. Chemical shifts are expressed in &#x3B4;-values (ppm) relative to TMS as an internal standard, using DMSO-<italic>d</italic><sub>6</sub> as a solvent. Mass spectra were recorded on a 600 GC/MS (Clarus, Middletown, CT, USA) and TQ 320 GC/MS/MS mass spectrometers (Varian, West Sussex, UK). Elemental analyses were done on a model 2400 CHNSO analyser (Perkin Elmer, Waltham, MA, USA). All the values were within &#xB1; 0.4% of the theoretical values. All reagents used were of AR grade. The starting material 4-chloro-2-phenylquinazoline was purchased from Sigma (St. Louis, MO, USA) and was directly used for the preparation of target compounds. Spectroscopic data of the synthesized compounds can be accessed as <xref ref-type="app" rid="app1-molecules-21-00189">supplementary materials</xref>.</p>
      </sec>
      <sec id="sec3dot2-molecules-21-00189">
        <title>3.2. General Procedure for the Synthesis of Sulfonamide Derivatives <bold>2</bold>&#x2013;<bold>18</bold></title>
        <p>A mixture of 4-chloro-2-phenylquinazoline (<bold>1</bold>, 2.42 g, 0.01 mol) and sulfonamides (0.012 mol) in dry dimethylformamide (10 mL) was refluxed for 22 h., then left to cool. The solid product formed upon pouring onto ice/water was collected by filtration and recrystallized from ethanol-dimethylformamide to give <bold>2</bold>&#x2013;<bold>18</bold>, respectively.</p>
        <p><italic>4-(2-Phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>2</bold>). Yield, 89%; m.p. 209.3 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3196, 3169, 3136 (NH, NH<sub>2</sub>), 3061 (CH arom.), 1670, 1602 (2C=N), 1394, 1190 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 7.4&#x2013;8.5 (m, 15H, Ar-H + SO<sub>2</sub>NH<sub>2</sub>), 9.7 (s, 1H, NH exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 114.4 (2), 121.4, 125.6, 126.3 (2), 127.0, 127.9, 128.3 (2), 128.8 (2), 129.2, 130.4, 131.1, 133.0, 139.1, 149.2, 152.7, 160.2. MS <italic>m</italic>/<italic>z</italic> (%): 376 (M<sup>+</sup>) (23.42), 74 (100). Anal. Calcd. For C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S (376): C, 63.81; H, 4. 28; N, 14.88. Found: C, 63.53; H, 4.50; N, 14.49.</p>
        <p><italic>N</italic><italic>-(4-(2-Phenylquinazolin-4-ylamino)phenylsulfonyl)acetamide</italic> (<bold>3</bold>). Yield, 91%; m.p. 243.5 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3412, 3269 (NH), 3100 (CH arom.), 2956, 2843 (CH aliph.), 1667 (C=O), 1602, 1571 (2C=N), 1344, 1189 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 1.9 (s, 3H, COCH3), 7.3&#x2013;8.7 (m, 14H, Ar-H + SO<sub>2</sub>NH), 12.5 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 23.6, 121.4 (2), 126.3, 126.8, 127.0 (2), 127.8 (2), 128.2 (2), 129.0, 129.1 (2), 131.8 (2), 133.1, 135.0, 149.0 (2), 152.8, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 418 (M<sup>+</sup>) (41.31), 122 (100). Anal. Calcd. For C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S (418): C, 63.14; H, 4. 34; N, 13.39. Found: C, 63.43; H, 4.10; N, 13.69.</p>
        <p><italic>N</italic><italic>-Carbamimidoyl-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>4</bold>). Yield, 78%; m.p. 314.4 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3425, 3329, 3186 (NH, NH<sub>2</sub>), 3100 (CH arom.), 2928,2868 (CH aliph.), 1669, 1618, 1601 (C=N), 1397,1169 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 6.7 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 7.1, 8.4 (m, 14H, Ar-H + SO<sub>2</sub>NH), 8.6 (s, 1H, NH imino, exchangeable with D<sub>2</sub>O) ,10.1 (s, 1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 114.4 (2), 121.4, 123.6, 126.3 (2), 127.0, 128.2, 128.4 (2), 129.0 (2), 131.0, 131.8, 133.1, 134.1, 139.5, 142.3, 158.2, 159.3, 162.7.MS <italic>m</italic>/<italic>z</italic> (%): 418 (M<sup>+</sup>) (25.4), 76 (100). Anal. Calcd. For C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>S (418): C, 60.27; H, 4. 34; N, 20.08. Found: C, 60.55; H, 4.09; N, 20.31.</p>
        <p><italic>N</italic><italic>-(3-Methylisoxazol-5-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>5</bold>). Yield, 83%; m.p. 133.4 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3323, 3196 (NH), 3061 (CH arom.), 2927, 2871 (CH aliph.), 1670, 1622, 1600 (C=N), 1357,1143 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 2.2 (s, 3H, CH<sub>3</sub>), 6.8 (s, 1H, CH isoxazole), 7.1&#x2013;8.6 (m, 13H, Ar-H),10.2 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O),12.5 (s,1H,NH exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>):10.9, 98.3, 114.5 (2), 114.7, 123.5, 126.3 (2), 126.6, 127.0, 128.2 (2), 128.9, 130.5 (2), 131.8, 132.7, 135.0, 141.6, 149.2, 158.1, 159.3, 162.7, 163.2. MS <italic>m</italic>/<italic>z</italic> (%): 458 (M<sup>+</sup>) (24.54), 81 (100). Anal. Calcd. For C<sub>24</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>S (458): C, 63.01; H, 4. 19; N, 15.31. Found: C, 63.29; H, 4.45; N, 15.61.</p>
        <p><italic>N</italic><italic>-(3,4-Dimethylisoxazol-5-yl)-4-(2-phenylquinazolin-4-yl-amino)benzenesulfonamide</italic> (<bold>6</bold>). Yield, 77%; m.p. 114.0 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3323, 3196 (NH), 3061 (CH arom.), 2927,2819 (CH aliph.), 1670, 1624 (C=N), 1373,1143 (SO<sub>2</sub>).<sup>1</sup> H-NMR (DMSO-<italic>d</italic><sub>6</sub>):2.6, 2.7 (2s, 6H, 2CH<sub>3</sub>), 7.3, 8.6 (m, 13H, Ar-H), 10.1 (s, 1H,SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 6.8, 10.8, 101.8, 114.5 (2), 114.7, 124.7, 126.6 (2), 127.2, 128.2, 128.6(2), 128.9, 129.0 (2), 130.5, 131.5, 132.7, 143.0, 149.2, 158.1, 159.3, 162.7, 163.2.MS <italic>m</italic>/<italic>z</italic> (%): 472 (M<sup>+</sup>) (4.7), 65 (100). Anal.Calcd. For C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>S (472): C, 63.68; H, 4. 49; N, 14.85. Found: C, 63.37; H, 4.27; N, 14.59.</p>
        <p><italic>N</italic><italic>-(1-Phenyl-1H-pyrazol-5-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>7</bold>). Yield, 89%; m.p. 232.6 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3196, 3134 (NH), 3064 (CH arom.), 1670, 1602 (C=N), 1340, 1190 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 7.4&#x2013;8.5 (m, 20H, Ar-H), 12.5 (s, 1H, SO<sub>2</sub>NH + NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 97.9, 115.2 (2), 121.4, 126.3 (2), 127.0 (2), 127.9, 128.2 (2), 128.3, 128.4, 128.7 (2), 128.9 (2), 129.0, 131.8 (2), 131.8, 133.2 (2), 135.0 (2), 149.2, 152.7, 162.7 (2). MS <italic>m</italic>/<italic>z</italic> (%): 519 (M<sup>+</sup>) (4.43), 103 (100). Anal.Calcd. For C<sub>29</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S (519): C, 67.17; H, 4. 28; N, 16.21. Found: C, 67.48; H, 4.52; N, 16.50.</p>
        <p><italic>4</italic><italic>-(2-Phenylquinazolin-4-ylamino)-N-(thiazol-2-yl)benzenesulfonamide</italic> (<bold>8</bold>). Yield, 79%; m.p. 146.7 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3487, 3381 (NH), 3084 (CH arom.), 1622, 1599 (C=N), 1358, 1178 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 6.8&#x2013;8.6 (m, 15H, Ar-H), 10.1 (s,1H,SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.7 (s, 1H,NH, exchangeable with D<sub>2</sub>O).<sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 108.5, 114.5 (2), 121.6, 124.9, 126.3 (2), 126.7, 127.0, 128.2 (2), 128.8, 130.9 (2), 131.8, 133.1, 133.9, 136.8, 143.2, 151.0, 158.1, 162.7, 169.1. MS <italic>m</italic>/<italic>z</italic> (%): 460 (M<sup>+</sup>) (9.59), 93 (100). Anal. Calcd. For C<sub>23</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub> (460): C, 60.11; H, 3.73; N, 15.24. Found: C, 60.43; H, 3.44; N, 15.50.</p>
        <p><italic>N</italic><italic>-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-</italic><italic>(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>9</bold>). Yield, 80%; m.p. 188.9 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3412, 3349 (NH), 3061 (CH arom.), 2923, 2859 (CH aliph.), 1622, 1600 (C=N), 1358,1184 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 2.4 (s, 3H<bold>,</bold> CH<sub>3</sub>), 7.3&#x2013;8.6 (m, 13H, Ar-H), 10.1 (s,1H,SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.9 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 16.5, 114.5 (2), 114.6, 124.9 (2), 126.3, 126.7, 127.9, 128.4, 129.0 (2), 130.7 (2), 131.8, 133.0, 134.0, 138.5, 143.6, 149.2, 152.7, 158.1, 168.2. MS <italic>m</italic>/<italic>z</italic> (%): 474 (M<sup>+</sup>) (20.8), 163 (100). Anal. Calcd. For C<sub>23</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>S<sub>2</sub> (474): C, 58.51; H, 3.82; N, 17.71. Found: C, 58.19; H, 3.58; N, 17.49.</p>
        <p><italic>4-(2-Phenylquinazolin-4-ylamino)-N-(pyridine-2-yl)benzenesulfonamide</italic> (<bold>10</bold>). Yield, 91%; m.p. 232.1 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3365, 3209 (NH), 3067 (CH arom.), 1635, 1600 (C=N), 1355, 1134 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 6.9&#x2013;8.5 (m, 17H, Ar-H), 10.3 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.8 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 114.0, 114.5 (2), 116.4, 121.4, 123.5, 126.4 (2), 127.0, 127.9, 128.3 (2), 129.0, 130.8 (2), 131.8, 132.7, 133.3, 135.9, 140.5, 149.2, 151.0, 153.4, 159.3, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 454 (M<sup>+</sup>) (28.2), 79 (100). Anal.Calcd. For C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>S (454): C, 66.21; H, 4. 22; N, 15.24. Found: C, 66.43; H, 4.52; N, 15.55.</p>
        <p><italic>4-(2-Phenylquinazolin-4-ylamino)-N-(pyrimidin-2-yl)benzenesulfonamide</italic> (<bold>11</bold>). Yield, 85%; m.p. 251.9 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3167, 3129 (NH), 3084 (CH arom.), 1635 (C=O), 1683, 1600 (C=N), 1392, 1159 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 6.9&#x2013;8.5 (m, 16H, Ar-H), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H, NH exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 114.5, 114.7 (2), 116.2, 124.7, 126.7 (2), 127.0, 128.2, 129.7 (2), 130.5, 130.9 (2), 131.8, 132.7, 133.1, 144.0, 149.2, 158.1 (2), 159.3, 162.7, 163.2. MS <italic>m</italic>/<italic>z</italic> (%): 455 (M<sup>+</sup>) (29.0), 158 (100). Anal. Calcd. For C<sub>24</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>S (455): C, 63.42; H, 3.99; N, 18.49. Found: C, 63.14; H, 4.32; N, 18.12.</p>
        <p><italic>N</italic><italic>-(4-Methylpyrimidin-2-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>12</bold>). Yield, 78%; m.p. 261.1 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3386, 3330 (NH), 3034 (CH arom.), 2962, 2870 (CH aliph.), 1624, 1599 (C=N), 1356,1147 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 2.3 (s, 3H, CH<sub>3</sub>), 6.9&#x2013;8.5 (m, 15H, Ar-H), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.7 (s, 1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>):23.7, 112.5, 114.5 (2), 115.3, 124.7, 126.5 (2), 127.0, 128.2, 128.4 (2), 129.0, 130.5 (2), 131.8, 132.8, 133.1, 143.9, 149.2, 152.7, 157.1, 162.7, 163.1, 168.7. MS <italic>m</italic>/<italic>z</italic> (%): 469 (M<sup>+</sup>) (4.36), 171 (100). Anal. Calcd. For C<sub>25</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (469): C, 64.09; H, 4.30; N, 17.94. Found: C, 64.30; H, 4.59; N, 17.68.</p>
        <p><italic>N</italic><italic>-(4,6-Dimethylpyrimidin-2-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>13</bold>). Yield, 90%; m.p. 232.8 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3365, 3196 (NH), 3064 (CH arom.), 2954, 2861 (CH aliph.), 1670, 1618, 1597 (C=N), 1355,1155 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 2.3 (s, 6H, 2CH<sub>3</sub>), 6.7 (s, 1H CH pyrimidine), 7.1&#x2013;8.6 (m, 13H, Ar-H), 10.0 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s,1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 24.3 (2), 114.5, 114.7 (2), 121.0, 124.8, 126.7 (2), 127.0, 127.9, 128.3, 128.7 (2), 129.5 (2), 130.3, 131.8, 133.1, 138.3, 149.2, 151.0, 159.3 (2), 162.7, 163.2. MS <italic>m</italic>/<italic>z</italic> (%): 483 (M<sup>+</sup>) (28.71), 109 (100). Anal. Calcd. For C<sub>26</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S (483): C, 64.71; H, 4. 60; N, 17.42. Found: C, 64.45; H, 4.29; N, 17.70.</p>
        <p><italic>N</italic><italic>-(5-Methoxypyrimidin-2-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>14</bold>). Yield, 84%; m.p. 264.6 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3423, 3221 (NH), 3100 (CH arom.), 2979, 2865 (CH aliph.), 1664, 1618, 1600 (C=N), 1356, 1161 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 3.7 (s, 3H, OCH<sub>3</sub>), 7.5&#x2013;8.6 (m, 15H, Ar-H), 10.3 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.4 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 56.7, 112.6 (2), 114.5, 126.3, 126.7, 127.9 (2), 128.3, 128.7 (2), 128.8, 129.3 (2), 130.9, 131.8, 134.6, 138.0 (2), 143.9, 145.0, 149.2, 158.1, 159.3, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 485 (M<sup>+</sup>) (21.87), 74 (100). Anal. Calcd. For C<sub>25</sub>H<sub>20</sub>N<sub>6</sub>O<sub>3</sub>S (485): C, 61.97; H, 4.16; N, 17.34. Found: C, 61.66; H, 4.33; N, 17.60.</p>
        <p><italic>N</italic><italic>-(2,6-Dimethoxypyrimidin-4-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>15</bold>). Yield, 87%; m.p. 367.8 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3221, 3169 (NH), 3057 (CH arom.), 2980, 2850 (CH aliph.), 1670, 1618, 1602 (C=N), 1388,1147 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 3.72, 3.79 (2s, 6H, 2OCH<sub>3</sub>), 6.1 (s, 1H, CH pyrimidine), 7.3&#x2013;8.8 (m, 13H, Ar-H), 10.0 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.4 (s, 1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 55.6 (2), 84.3, 114.4 (2), 121.4, 123.6, 126.7 (2), 127.0, 127.9, 128.4 (2), 129.9, 130.9 (2), 131.8, 133.1, 135.0, 142.9, 149.1, 156.0, 159.3, 161.7, 162.6, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 515 (M<sup>+</sup>) (5.19), 154 (100). Anal. Calcd. For C<sub>26</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S (515): C, 60.69; H, 4.31; N, 16.33. Found: C, 60.40; H, 4.62; N, 16.03.</p>
        <p><italic>N</italic><italic>-(5,6-Dimethoxypyrimidin-4-yl)-4-(2-phenylquinazolin-4-yl-amino)benzenesulfonamide</italic> (<bold>16</bold>). Yield, 79%; m.p. 139.0 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3360, 3192 (NH), 3059 (CH arom.), 2941, 2863 (CH aliph.), 1670, 1602 (C=N), 1328, 1188 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 3.73, 3.74 (2s, 6H, 2OCH<sub>3</sub>), 7.2&#x2013;8.2 (m, 14H, Ar-H), 8.5 (s, 1H, CH pyrimidine), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H,NH, exchangeable with D<sub>2</sub>O).<sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 59.4 (2), 114.5 (2), 114.6, 125.0, 126.5 (2), 127.9, 128.2, 128.4 (2), 129.0, 130.2 (2), 130.6, 131.8, 133.1, 134.0, 143.9, 147.2, 152.7, 158.2, 159.3, 162.7, 162.8. MS <italic>m</italic>/<italic>z</italic> (%): 515 (M<sup>+</sup>) (28.12), 168 (100). Anal. Calcd. For C<sub>26</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S (515): C, 60.69; H, 4.31; N, 16.33. Found: C, 60.44; H, 4.04; N, 16.09.</p>
        <p><italic>N</italic><italic>-(1H-Indazol-6-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</italic> (<bold>17</bold>). Yield, 89%; m.p. 149.9 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3192, 3134 (NH), 3062 (CH arom.), 1635, 1624, 1600 (C=N), 1375, 1149 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 6.9&#x2013;8.4 (m, 17H, Ar-H), 8.5, 10.1 (2s, 2H, SO<sub>2</sub>NH + NH, exchangeable with D<sub>2</sub>O), 12.9 (s, 1H, NH pyrazole, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 100.5, 114.5, 114.8, 115.4 (2), 120.2, 121.3, 124.7, 126.3 (2), 127.0, 127.9, 128.2 (2), 128.6, 130.5 (2), 130.8, 131.8, 132.7, 133.2, 140.8, 144.0, 151.0, 158.3, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 493 (M<sup>+</sup>) (30.31), 117 (100). Anal. Calcd. For C<sub>27</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (493): C, 65.84; H, 4.09; N, 17.06. Found: C, 65.46; H, 4.30; N, 17.29.</p>
        <p><italic>4-(2-Phenylquinazolin-4-ylamino)-N-(quinoxalin2-yl)benzenesulfonamide</italic> (<bold>18</bold>). Yield, 76%; m.p. 154.8 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3194, 3134 (NH), 3059 (CH arom.), 1670, 1600 (C=N), 1338, 1161 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 7.4&#x2013;8.6 (m, 18H, Ar-H), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 114.5 (2), 114.6, 121.4, 123.5, 124.9, 126.3 (2), 126.5, 127.0, 127.7, 127.9, 128.2 (2), 128.7, 129.0, 129.2, 130.6, 130.9, 133.1, 134.0, 135.0, 138.4, 144.3, 146.6, 152.7, 162.7, 163.2. MS <italic>m</italic>/<italic>z</italic> (%): 505 (M<sup>+</sup>) (26.73), 175 (100). Anal.Calcd. For C<sub>28</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (505): C, 66.65; H, 4.00; N, 16.66. Found: C, 66.93; H, 4.31; N, 16.34.</p>
        <p><italic>4-Amino-N-(2-phenylquinazolin-4-yl)benzenesulfonamide</italic> (<bold>19</bold>). A mixture of compound 1 (2.42 g, 0.01 mol), sulfanilamide (1.72 g, 0.01 mol) and anhydrous potassium carbonate (1.38 g, 0.01 mol) in dry dimethylformamide (15 mL) was refluxed for 18 h. The obtained solid was recrystallized from dioxane to give 19. Yield, 68%; m.p. 245.9 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3394, 3209 (NH, NH<sub>2</sub>), 3059 (CH arom.), 1635, 1608 (C=N), 1375, 1134 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 7.0 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 7.5&#x2013;9.0 (m, 13H, Ar-H], 11.9 [s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O]. <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 113.2 (2), 116.6, 124.4, 126.3 (2), 127.7, 127.8, 128.7 (2), 129.2, 129.8 (2), 131.7, 132.4, 132.8, 141.6, 157.7, 159.9, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 376 (M<sup>+</sup>) (22.25), 155 (100). Anal.Calcd. For C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S (376): C, 63.81; H, 4.28; N, 14.88. Found: C, 63.54; H, 4.01; N, 14.56.</p>
        <p><italic>N</italic><italic>-(4-(4-Aminophenylsulfonyl)phenyl)-2-phenylquinazolin-4-amine</italic> (<bold>20</bold>). A mixture of 1 (2.42 g, 0.01 mol) and dapsone (2.48 g, 0.01 mol) in dry dimethylformamide (10 mL) was refluxed for 12 h. The obtained solid while hot was recrystallized from dioxane to give 20. Yield, 77%; m.p. 116.8 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3415, 3375(NH, NH<sub>2</sub>), 3059 (CH arom.), 1618, 1595 (C=N), 1369, 1140 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 5.9 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 6.5&#x2013;8.6 (m, 17H, Ar-H), 10.1 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 113.3 (2), 114.4 (2), 114.5, 122.9, 125.7 (2), 126.3, 127.0, 128.1 (2), 129.2 (4), 129.7, 130.2 (2), 131.8, 133.0, 143.8, 149.2, 152.7, 159.7, 162.7. MS <italic>m</italic>/<italic>z</italic> (%): 453 (M<sup>+</sup>) (32.53), 92 (100). Anal. Calcd. For C<sub>26</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S (453): C, 69.01; H, 4.45; N, 12.28. Found: C, 69.32; H, 4.71; N, 12.49.</p>
        <p><italic>N</italic><italic>,N&#x2032;-(4,4&#x2032;-Sulfonylbis(4,1-phenylene)bis(2-phenylquinazolin-4-amine)</italic> (<bold>21</bold>). A mixture of 1 (4.84 g, 0.02 mol) and dapsone (2.48 g, 0.01 mol) in dry dimethylformamide (10 mL) was refluxed for 18 h. The obtained solid while hot was recrystallized from acetic acid to give 21. Yield, 68%; m.p. 197.9 &#xB0;C. IR (KBr, cm<sup>&#x2212;1</sup>): 3367, 3195 (NH), 3060 (CH arom.), 1622, 1597 (C=N), 1385, 1181 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<italic>d</italic><sub>6</sub>): 7.4&#x2013;8.6 (m, 26H, Ar-H), 10.1 (s, 2H, 2NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<italic>d</italic><sub>6</sub>): 113.4 (4), 114.5 (2), 126.3 (2), 126.8 (2), 127.9 (4), 128.2 (2), 128.6 (4), 129.7 (4), 131.8 (2), 133.1 (2), 134.0(2), 135.0 (2), 143.8 (2), 149.2 (2), 153.9 (2), 158.1 (2). MS <italic>m</italic>/<italic>z</italic> (%): 657 (M<sup>+</sup>) (9.30), 271(100). Anal. Calcd. For C<sub>40</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>S (657): C, 73.15; H, 4.30; N, 12.80. Found: C, 73.37; H, 4.66; N, 13.09.</p>
      </sec>
      <sec id="sec3dot3-molecules-21-00189">
        <title>3.3. In-Vitro Anticancer Evaluation</title>
        <sec id="sec3dot3dot1-molecules-21-00189">
          <title>3.3.1. Cell Culture</title>
          <p>Human cancer cell lines HeLa (cervical), A549 (lungs) and LoVo (colorectal) were grown in DMEM + GlutaMax (Invitrogen, Carlsbad, CA, USA), and MDA-MB-231 (breast) were grown in DMEM-F12 + GlutaMax) medium (Invitrogen), supplemented with 10% heat-inactivated bovine serum (Gibco) and penicillin-streptomycin (Gibco, Gaithersburg, MD, USA) at 37 &#xB0;C in a humified chamber with 5% CO<sub>2</sub> supply.</p>
        </sec>
        <sec id="sec3dot3dot2-molecules-21-00189">
          <title>3.3.2. Cytotoxicity Assay</title>
          <p>The <italic>in vitro</italic> anticancer screening was done at Pharmacognosy Department, College of Pharmacy, King Saud University (Riyadh, Saudi Arabia). Cells were seeded (10<sup>5</sup> cells/well) in 96-well flat-bottom plates (Becton-Dickinson Labware, Franklin Lakes, NJ, USA) a day before treatment and grown overnight. Compounds were dissolved in dimethyl sulfoxide (DMSO; Sigma) and finally prepared as 1.0 mg/mL stocks, respectively in the culture media. The final concentration of DMSO never exceeded 0.1% in the treatment doses. Six different doses of compounds (400, 200, 100, 50, 25 and 10 &#xB5;M) were further prepared by diluting the stocks in culture media, and cells were treated (in triplicate/dose). Doxorubicin was included as standard reference drug (positive control) and untreated culture was considered as negative control. The cultures were further incubated for 48 hrs. At 48 h post-treatment, cell viability test was performed using TACS MTT Cell Proliferation and Viability Assay Kit (TACS) as per manufacturer&#x2019;s instructions. The optical density (OD) was recorded at 570 nm in a microplate reader (ELx800, BioTek, Winooski, VT, USA) and cell survival fraction was determined. The cell survival fraction was calculated as [(A &#x2212; B)/A], where A and B are the OD of untreated and of treated cells, respectively. The relation between surviving fraction and drug concentration is plotted to get the survival curve of each tumor cell line after the specified time. The concentration required for 50% inhibition of cell viability (IC<sub>50</sub>) was calculated and compared with the reference drug doxorubicin and the results are given in <xref ref-type="table" rid="molecules-21-00189-t001">Table 1</xref>. Surviving curves for doxorubicin can be accessed as <xref ref-type="app" rid="app1-molecules-21-00189">supplementary materials</xref>.</p>
        </sec>
      </sec>
    </sec>
    <sec id="sec4-molecules-21-00189" sec-type="conclusions">
      <title>4. Conclusions</title>
      <p>In this work, novel quinazoline-sulfonamide hybrids were synthesized and their <italic>in vitro</italic> anticancer activity was evaluated on four human cancer cell lines, among the tested compounds, two candidates (compounds <bold>7</bold> and <bold>17</bold>) showed effectiveness on the four cell lines, the active compounds could be considered as useful templates for further development to obtain more potent anticancer agent(s).</p>
    </sec>
  </body>
  <back>
  <app-group>
     <app id="app1-molecules-21-00189">
      <title>Supplementary Materials</title>
	  <supplementary-material id="molecules-21-00189-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-21-00189-s001.pdf">
    </supplementary-material>
      <p>Supplementary materials can be accessed at: <uri>http://www.mdpi.com/1420-3049/21/2/189/s1</uri>.</p>
    </app>
	</app-group>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project No. RGP-VPP-302.</p>
    </ack>
    <notes>
      <title>Author Contributions</title>
      <p>M.M.G. suggested the research idea, contributed in the experimental work and in writing the paper. M.S.A. contributed in the experimental work, the biological activity and in writing the paper. M.S.A.-D., M.K.P. contributed in the biological activity. M.G.E.-G. contributed in the experimental work.</p>
    </notes>
    <notes>
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-molecules-21-00189">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Medina</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Roche</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Learned</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Frankmoelle</surname>
              <given-names>W.P.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Jaen</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>1999</year>
          <volume>9</volume>
          <fpage>1843</fpage>
          <lpage>1846</lpage>
          <pub-id pub-id-type="pmid">10406652</pub-id>
        </citation>
      </ref>
      <ref id="B2-molecules-21-00189">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hwang</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>E.Y.</given-names>
            </name>
            <name>
              <surname>Seong</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of the anticancer activity of DW2282, a new anticancer agent</article-title>
          <source>Anticancer Res.</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>5087</fpage>
          <lpage>5093</lpage>
          <pub-id pub-id-type="pmid">10697515</pub-id>
        </citation>
      </ref>
      <ref id="B3-molecules-21-00189">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choo</surname>
              <given-names>H.Y.P.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S.W.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>S.W.</given-names>
            </name>
          </person-group>
          <article-title>Solid-phase combinatorial synthesis and cytotoxicity of 3-aryl-2,4-quinazolindiones</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2002</year>
          <volume>10</volume>
          <fpage>517</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">11814837</pub-id>
        </citation>
      </ref>
      <ref id="B4-molecules-21-00189">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antonello</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tarozzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Morroni</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Cavalli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rosini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hrelia</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bolognesi</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Melchiorre</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Multitarget-directed drug design strategy: A novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects</article-title>
          <source>J. Med. Chem.</source>
          <year>2006</year>
          <volume>49</volume>
          <fpage>6642</fpage>
          <lpage>6645</lpage>
          <pub-id pub-id-type="pmid">17154492</pub-id>
        </citation>
      </ref>
      <ref id="B5-molecules-21-00189">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rachid</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Brahimi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Jean-Claude</surname>
              <given-names>B.J.</given-names>
            </name>
          </person-group>
          <article-title>Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure activity relationship</article-title>
          <source>J. Med. Chem.</source>
          <year>2007</year>
          <volume>50</volume>
          <fpage>2605</fpage>
          <lpage>2608</lpage>
          <pub-id pub-id-type="pmid">17472358</pub-id>
        </citation>
      </ref>
      <ref id="B6-molecules-21-00189">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baselga</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Swain</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3</article-title>
          <source>Nat. Rev. Cancer</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>463</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="doi">10.1038/nrc2656</pub-id>
          <pub-id pub-id-type="pmid">19536107</pub-id>
        </citation>
      </ref>
      <ref id="B7-molecules-21-00189">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>C.H.J.</given-names>
            </name>
            <name>
              <surname>Lain</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>C.H.S.</given-names>
            </name>
            <name>
              <surname>Fersht</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <article-title>Awakening guardian angels: Drugging the p53 pathway</article-title>
          <source>Nat. Rev. Cancer</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>862</fpage>
          <lpage>873</lpage>
          <pub-id pub-id-type="pmid">19935675</pub-id>
        </citation>
      </ref>
      <ref id="B8-molecules-21-00189">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X.H.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>H.B.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>H.L.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, biological evaluation, and molecular docking studies of <italic>N</italic>,1,3-triphenyl-1<italic>H</italic>-pyrazole-4 carboxamide derivatives as anticancer agents</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>3589</fpage>
          <lpage>3593</lpage>
          <pub-id pub-id-type="pmid">22572580</pub-id>
        </citation>
      </ref>
      <ref id="B9-molecules-21-00189">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kidwai</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Venkataramanan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Mohan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sapra</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Chemotherapy and heterocyclic compounds</article-title>
          <source>Curr. Med. Chem.</source>
          <year>2002</year>
          <volume>9</volume>
          <fpage>1209</fpage>
          <lpage>1228</lpage>
          <pub-id pub-id-type="pmid">12052173</pub-id>
        </citation>
      </ref>
      <ref id="B10-molecules-21-00189">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salimon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Salih</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Yousif</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hameed</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ibraheem</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and antibacterial activity of some new 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives</article-title>
          <source>Aust. J. Basic Appl. Sci.</source>
          <year>2010</year>
          <volume>4</volume>
          <fpage>2016</fpage>
          <lpage>2021</lpage>
        </citation>
      </ref>
      <ref id="B11-molecules-21-00189">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohamed</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Lake</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Laing</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Willans</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and anticancer activity of silver(I)-<italic>N</italic>-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine</article-title>
          <source>Dalton Trans.</source>
          <year>2015</year>
          <volume>44</volume>
          <fpage>7563</fpage>
          <lpage>7569</lpage>
          <pub-id pub-id-type="pmid">25812062</pub-id>
        </citation>
      </ref>
      <ref id="B12-molecules-21-00189">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srivastava</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Mukherjee</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Burman</surname>
              <given-names>A.C.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of quinazolines as tyrosine kinase inhibitors</article-title>
          <source>Anticancer Agents Med. Chem.</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>246</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.2174/1871520610909030246</pub-id>
          <pub-id pub-id-type="pmid">19275520</pub-id>
        </citation>
      </ref>
      <ref id="B13-molecules-21-00189">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruz-L&#xF3;pez</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Conejo-Garc&#xED;a</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>N&#xFA;&#xF1;ez</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Kimatrai</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Rubi&#xF1;o</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Morales</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>G&#xF3;mez-P&#xE9;rez</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors</article-title>
          <source>Curr. Med. Chem.</source>
          <year>2011</year>
          <volume>18</volume>
          <fpage>943</fpage>
          <lpage>963</lpage>
          <pub-id pub-id-type="pmid">21254978</pub-id>
        </citation>
      </ref>
      <ref id="B14-molecules-21-00189">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garofalo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Goossens</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Six</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lemoine</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ravez</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Farce</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Depreux</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>2106</fpage>
          <lpage>2112</lpage>
          <pub-id pub-id-type="pmid">21353546</pub-id>
        </citation>
      </ref>
      <ref id="B15-molecules-21-00189">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xFC;th</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>L&#xF6;we</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Syntheses of 4-(indole-3-yl)quinazolines: A new class of epidermal growth factor receptor tyrosine kinase inhibitors</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2008</year>
          <volume>43</volume>
          <fpage>1478</fpage>
          <lpage>1488</lpage>
          <pub-id pub-id-type="pmid">17981366</pub-id>
        </citation>
      </ref>
      <ref id="B16-molecules-21-00189">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>B.S.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors</article-title>
          <source>Arch. Pharm.</source>
          <year>2005</year>
          <volume>338</volume>
          <fpage>502</fpage>
          <lpage>505</lpage>
        </citation>
      </ref>
      <ref id="B17-molecules-21-00189">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cui</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zha</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib insensitive esophageal squamous cancer cells</article-title>
          <source>Med. Oncol.</source>
          <year>2015</year>
          <volume>32</volume>
          <fpage>570</fpage>
          <lpage>76</lpage>
        </citation>
      </ref>
      <ref id="B18-molecules-21-00189">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mathew</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Saeui</surname>
              <given-names>C.T.</given-names>
            </name>
            <name>
              <surname>Bovonratwet</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bhattacharya</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yarema</surname>
              <given-names>K.J.</given-names>
            </name>
          </person-group>
          <article-title>Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2015</year>
          <volume>25</volume>
          <fpage>1223</fpage>
          <lpage>1227</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmcl.2015.01.060</pub-id>
          <pub-id pub-id-type="pmid">25690786</pub-id>
        </citation>
      </ref>
      <ref id="B19-molecules-21-00189">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bellizzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Rubino</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Paradiso</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Forciniti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zeeberg</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Cardone</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Reshkin</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells</article-title>
          <source>Int. J. Oncol.</source>
          <year>2015</year>
          <volume>46</volume>
          <fpage>1214</fpage>
          <lpage>1224</lpage>
          <pub-id pub-id-type="pmid">25530180</pub-id>
        </citation>
      </ref>
      <ref id="B20-molecules-21-00189">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackman</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Cioffredi</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Sharmeen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Morse</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Lucca</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Plotkin</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Marcoux</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Rabin</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>T.J.</given-names>
            </name> 
            <name>
              <surname>Johnson</surname>
              <given-names>B.E.</given-names>
            </name>
			<etal/>
          </person-group>
          <article-title>A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer</article-title>
          <source>Oncotarget</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>4527</fpage>
          <lpage>4536</lpage>
          <pub-id pub-id-type="pmid">25784657</pub-id>
        </citation>
      </ref>
      <ref id="B21-molecules-21-00189">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakao</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Muramatsu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sone</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Akiko</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kagawa</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kunieda</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis</article-title>
          <source>Mol. Clin. Oncol.</source>
          <year>2015</year>
          <volume>3</volume>
          <fpage>403</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="pmid">25798276</pub-id>
        </citation>
      </ref>
      <ref id="B22-molecules-21-00189">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koizumi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer</article-title>
          <source>Ann. Palliat. Med.</source>
          <year>2013</year>
          <volume>2</volume>
          <fpage>111</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="pmid">25842091</pub-id>
        </citation>
      </ref>
      <ref id="B23-molecules-21-00189">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nolting</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schneider-Merck</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Trepel</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Lapatinib</article-title>
          <source>Recent Results Cancer Res.</source>
          <year>2014</year>
          <volume>201</volume>
          <fpage>125</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="pmid">24756789</pub-id>
        </citation>
      </ref>
      <ref id="B24-molecules-21-00189">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brassard</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rondeau</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Role of vandetanib in the management of medullary thyroid cancer</article-title>
          <source>Biologics</source>
          <year>2012</year>
          <volume>6</volume>
          <fpage>59</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">22500115</pub-id>
        </citation>
      </ref>
      <ref id="B25-molecules-21-00189">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levitzki</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Tyrosine kinases as targets for cancer therapy</article-title>
          <source>Eur. J. Cancer</source>
          <year>2002</year>
          <volume>38</volume>
          <fpage>S11</fpage>
          <lpage>S18</lpage>
          <pub-id pub-id-type="pmid">12528768</pub-id>
        </citation>
      </ref>
      <ref id="B26-molecules-21-00189">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harakeh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Assef</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>El-Sabban</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Haddadin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Muhatasib</surname>
              <given-names>H.G.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of proliferation and induction of apoptosis bt 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adults T-cell leukemia cells</article-title>
          <source>Chem. Biol. Interact.</source>
          <year>2004</year>
          <volume>148</volume>
          <fpage>101</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="pmid">15276867</pub-id>
        </citation>
      </ref>
      <ref id="B27-molecules-21-00189">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levitzki</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Protein tyrosine kinase inhibitors as noveltherapeutic agents</article-title>
          <source>Pharmacol. Ther.</source>
          <year>1999</year>
          <volume>82</volume>
          <fpage>231</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">10454200</pub-id>
        </citation>
      </ref>
      <ref id="B28-molecules-21-00189">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bogoyevitch</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Fairlie</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <article-title>A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding</article-title>
          <source>Drug Discov. Today</source>
          <year>2007</year>
          <volume>12</volume>
          <fpage>622</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.1016/j.drudis.2007.06.008</pub-id>
          <pub-id pub-id-type="pmid">17706543</pub-id>
        </citation>
      </ref>
      <ref id="B29-molecules-21-00189">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drews</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Drug discovery: A historical perspective</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>287</volume>
          <fpage>1960</fpage>
          <lpage>1964</lpage>
          <pub-id pub-id-type="doi">10.1126/science.287.5460.1960</pub-id>
          <pub-id pub-id-type="pmid">10720314</pub-id>
        </citation>
      </ref>
      <ref id="B30-molecules-21-00189">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Supuran</surname>
              <given-names>C.T.</given-names>
            </name>
            <name>
              <surname>Casini</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mastrolorenzo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Scozzafava</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents</article-title>
          <source>Mini Rev. Med. Chem.</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>625</fpage>
          <lpage>632</lpage>
          <pub-id pub-id-type="pmid">15279596</pub-id>
        </citation>
      </ref>
      <ref id="B31-molecules-21-00189">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abbate</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Casini</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Owa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Scozzafava</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Supuran</surname>
              <given-names>C.T.</given-names>
            </name>
          </person-group>
          <article-title>Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>217</fpage>
          <lpage>223</lpage>
          <pub-id pub-id-type="pmid">14684331</pub-id>
        </citation>
      </ref>
      <ref id="B32-molecules-21-00189">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solomon</surname>
              <given-names>V.R.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>7585</fpage>
          <lpage>7592</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2009.08.068</pub-id>
          <pub-id pub-id-type="pmid">19804979</pub-id>
        </citation>
      </ref>
      <ref id="B33-molecules-21-00189">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Ragab</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Heiba</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>El-Gazzar</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Zahran</surname>
              <given-names>S.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2015</year>
          <volume>92</volume>
          <fpage>682</fpage>
          <lpage>692</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2015.01.036</pub-id>
          <pub-id pub-id-type="pmid">25618015</pub-id>
        </citation>
      </ref>
      <ref id="B34-molecules-21-00189">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Alsaid</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Ceruso</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nissan</surname>
              <given-names>Y.M.</given-names>
            </name>
            <name>
              <surname>Supuran</surname>
              <given-names>C.T.</given-names>
            </name>
          </person-group>
          <article-title>Carbonic anhydrase inhibitors: Synthesis, molecular docking, cytotoxic and inhibition of the human carbonic anhydrase isoforms I, II, IX, XII with novel benzenesulfonamides incorporating pyrrole, pyrrolopyrimidine and fused pyrrolopyrimidine moieties</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>3684</fpage>
          <lpage>3695</lpage>
        </citation>
      </ref>
      <ref id="B35-molecules-21-00189">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Ceruso</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Alsaid</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Nissan</surname>
              <given-names>Y.M.</given-names>
            </name>
            <name>
              <surname>Arafa</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Supuran</surname>
              <given-names>C.T.</given-names>
            </name>
          </person-group>
          <article-title>Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic anhydrase inhibitors: Synthesis, cytotoxic activity and molecular modeling</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2014</year>
          <volume>87</volume>
          <fpage>186</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="pmid">25255434</pub-id>
        </citation>
      </ref>
      <ref id="B36-molecules-21-00189">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>El-Gazzar</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Alsaid</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and Anti-Breast Cancer Evaluation of Novel <italic>N</italic>-(Guanidinyl)-benzenesulfonamides</article-title>
          <source>Int. J. Mol. Sci.</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>5582</fpage>
          <lpage>5595</lpage>
          <pub-id pub-id-type="doi">10.3390/ijms15045582</pub-id>
          <pub-id pub-id-type="pmid">24694543</pub-id>
        </citation>
      </ref>
      <ref id="B37-molecules-21-00189">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>El-Gazzar</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Alsaid</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, Characterization and Anti-Breast Cancer Activity of New 4-Aminoantipyrine-Based Heterocycles</article-title>
          <source>Int. J. Mol. Sci.</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>7539</fpage>
          <lpage>7553</lpage>
          <pub-id pub-id-type="pmid">24798749</pub-id>
        </citation>
      </ref>
      <ref id="B38-molecules-21-00189">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Dosari</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Alsaid</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Nissan</surname>
              <given-names>Y.M.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and anticancer activity of some novel trifluoromethylquinolines carrying a biologically active benzenesulfonamide moiety</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2013</year>
          <volume>69</volume>
          <fpage>373</fpage>
          <lpage>383</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2013.08.048</pub-id>
          <pub-id pub-id-type="pmid">24077528</pub-id>
        </citation>
      </ref>
      <ref id="B39-molecules-21-00189">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Ragab</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Heiba</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>El-Hazek</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2011</year>
          <volume>46</volume>
          <fpage>5120</fpage>
          <lpage>5126</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2011.08.026</pub-id>
          <pub-id pub-id-type="pmid">21890248</pub-id>
        </citation>
      </ref>
      <ref id="B40-molecules-21-00189">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Said</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Al-Dosari</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Hamed</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and <italic>in vitro</italic> anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2011</year>
          <volume>46</volume>
          <fpage>201</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="pmid">21112675</pub-id>
        </citation>
      </ref>
      <ref id="B41-molecules-21-00189">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Ragab</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Heiba</surname>
              <given-names>H.I.</given-names>
            </name>
            <name>
              <surname>Youssef</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>El-Gazzar</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of novel pyrrole and pyrrolo [2,3-d] pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>6316</fpage>
          <lpage>6320</lpage>
          <pub-id pub-id-type="pmid">20850308</pub-id>
        </citation>
      </ref>
      <ref id="B42-molecules-21-00189">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Said</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Al-Qasoumi</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>El-Hossary</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Noaman</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and <italic>in vitro</italic> anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4<italic>H</italic>)-yl]benzenesulfonamides</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2011</year>
          <volume>45</volume>
          <fpage>3011</fpage>
          <lpage>3018</lpage>
        </citation>
      </ref>
      <ref id="B43-molecules-21-00189">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alqasoumi</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Al-Taweel</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Alafeefy</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Noaman</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>1849</fpage>
          <lpage>1853</lpage>
          <pub-id pub-id-type="pmid">20149941</pub-id>
        </citation>
      </ref>
      <ref id="B44-molecules-21-00189">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alqasoumi</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Al-Taweel</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Alafeefy</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Noaman</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>738</fpage>
          <lpage>744</lpage>
          <pub-id pub-id-type="pmid">19944497</pub-id>
        </citation>
      </ref>
      <ref id="B45-molecules-21-00189">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghorab</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Ragab</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Hamed</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>4211</fpage>
          <lpage>4217</lpage>
          <pub-id pub-id-type="pmid">19540022</pub-id>
        </citation>
      </ref>
      <ref id="B46-molecules-21-00189">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paul</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Luxami</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and <italic>in vitro</italic> antitumor evaluation of primary amine substituted quinazoline linked benzimidazole</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2014</year>
          <volume>24</volume>
          <fpage>624</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="pmid">24360999</pub-id>
        </citation>
      </ref>
    </ref-list>
	<fn-group><fn><p><bold>Sample Availability:</bold> Not available.</p></fn></fn-group>
  </back>
</article>
